

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 6-KREPORT
OFFOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT
OF 1934For the monthof June 2025Commission FileNo. 001-38691AURORACANNABIS INC.(Translation of registrant's
name into English)Â 2207 90B St. SW Edmonton, Alberta T6X 1V8 Canada(Address of principal executive
office)Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form
40-FForm 20-FA Â ~'Â Â Â SUBMITTED HEREWITHÂ Exhibits DescriptionÂ 99.1 Â News
release dated June 18, 2025Â Â Â SIGNATUREPursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.AURORA CANNABIS INC./s/ Miguel MartinÂ Miguel MartinChief Executive OfficerDate: June 18, 2025
Exhibit 99.1Â Â Aurora Cannabis Denies News of Acquisition ofMedLeaf TherapeuticsNASDAQ | TSX:

ACBEDMONTON, AB, June 18, 2025 /CNW/ -Â Aurora CannabisInc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabiscompany, has become aware of misinformation posted on a news website, incorrectly stating that Aurora has agreed to acquire New Zealandbased MedLeaf Therapeutics. The Company has not entered into any such agreement, has had no discussions with MedLeaf Therapeutics withrespect to any business combination transaction, and has not made any statement or filed any information pertaining to any such transaction.Earlier today before market open, Aurora filed theCompany's financial statements and management's discussion and analysis for the fourth quarter and fiscal year ending March 31, 2025.All information pertaining to these disclosures is available on the Company's website at www.auroramj.com and on SEDAR+ and EDGAR.About Aurora CannabisAurora is opening the world to cannabis, serving boththe medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneerin global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael'71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical MarijuanaCo., as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd.,North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-qualitycannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational marketswherever they are launched. Learn more atÂ www.auroramj.com and follow us onÂ X and LinkedIn.Aurora's common shares trade on the NASDAQ and TSXunder the symbol "ACB".Forward Looking InformationÂ This news release includes statements containing certain"forward-looking information" within the meaning of applicable securities law ("forward-looking statements").Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur.These forward-looking statements are only predictions.Forward looking information or statements contained in this news release have been developed based on assumptions management considersto be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publiclyavailable information from governmental sources as well as from market research and industry analysis and on assumptions based on dataand knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks,uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events,results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-lookingstatements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goodsimported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructureto support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience andretention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demandin Canada and in jurisdictions where the Company exports, expectations of future results and expenses,Â the ability to expand andmaintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabisgrowing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set outunder the heading "Risk Factors" in the Company's annual information form dated June 17, 2025Â (the "AIF") andfiled with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.comÂ and filed withand available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors describedin the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertaintiesand assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information.The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements,whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.View original content to download multimedia:<https://www.prnewswire.com/news-releases/aurora-cannabis-denies-news-of-acquisition-of-medleaf-therapeutics-302485728.html>SOURCE Aurora Cannabis Inc.View original content to download multimedia:<http://www.newswire.ca/en/releases/archive/June2025/18/c3927.html>CIK: 0001683541For further information: For Media: Michelle Lefler, VP, Communications& PR, media@auroramj.com; For Investors: ICR, Inc., Investor Relations, aurora@icrinc.comCO: Aurora Cannabis Inc.CNW 16:34e 18-JUN-25